Bio Pharma Dive
JULY 26, 2024
Eisai plans to appeal the EMA’s negative recommendation, hoping to break into a market analysts expect could eventually bring billions of dollars in sales for the Alzheimer’s drug.
Worldwide Clinical Trials
JULY 26, 2024
At Worldwide Clinical Trials’ bioanalytical lab, we view challenges as opportunities to excel and set new standards. The path to drug approval is complex, with many variables and potential delays. That’s why our team is committed to continuous improvement through our initiative, WorldwideEdge, where we optimize everything from our processes to our teams’ performance for each drug development program.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Bio Pharma Dive
JULY 26, 2024
All five large pharmaceutical companies to report earnings this week raised either their profit or revenue guidance for the year.
Pharmaceutical Technology
JULY 26, 2024
The European Commission has awarded conditional marketing authorisation for Pfizer's DURVEQTIX for haemophilia B treatment.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
Bio Pharma Dive
JULY 26, 2024
Glycomimetics and Cue Biopharma both revealed layoffs. Elsewhere, AbbVie’s earnings impressed Wall Street and an FDA panel recommended changing testing requirements for some lung cancer drugs.
Pharmaceutical Technology
JULY 26, 2024
Mankind Pharma has announced a definitive agreement for the acquisition of Bharat Serums and Vaccines (BSV) for Rs136.3bn ($1.6bn).
Clinical Research Informer brings together the best content for clinical researchers from the widest variety of industry thought leaders.
Pharmaceutical Technology
JULY 26, 2024
The ODAC highlighted that perioperative trials should separately evaluate the effectiveness of treatments pre- and post-operation.
Pharma Times
JULY 26, 2024
The new Human Gut Microbiome Atlas could help treat conditions including IBS and AMR
Pharmaceutical Technology
JULY 26, 2024
The current approval, which is based on data from non-human primates and healthy individuals, will be updated with real-world observations.
pharmaphorum
JULY 26, 2024
CHMP recommends against approval of Eisai, Biogen's Alzheimer's disease therapy Leqembi, saying side effects outweigh its benefits
Pharmaceutical Technology
JULY 26, 2024
The FDA approval is based on data gathered from two Phase III studies where over 30% of the patients gained 80% or more coverage of scalp hair.
Fierce Pharma
JULY 26, 2024
Despite winning approvals in a range of countries like the U.S., China, Japan and Israel, Eisai and Biogen’s anti-amyloid Alzheimer’s disease med Leqembi has come up short in the eyes of European r | Despite winning approvals in a range of countries like the U.S., China and Japan, Eisai and Biogen’s anti-amyloid Alzheimer’s disease med Leqembi has come up short in the eyes of European regulators.
Pharmaceutical Technology
JULY 26, 2024
The EMA recommended a label update that allows the drug to be used to reduce cardiovascular risk.
Fierce Pharma
JULY 26, 2024
Amid the sturm und drang over Inflation Reduction Act (IRA) drug price negotiations, Bristol Myers Squibb has been among the biopharma companies casting the most woe over the oncoming measures. | Bristol Myers Squibb CEO Chris Boerner said after seeing the final negotiated price for Eliquis that he is "increasingly confident" the company can navigate the impact of the IRA.
Advertisement
White paper that delves into the complex topic of Decentralized Clinical Trials and how to master them within the confines of FDA Regulations
Pharmaceutical Technology
JULY 26, 2024
The company has fired 25% of its staff and plans to look for partnerships to further its oncology candidates.
Fierce Pharma
JULY 26, 2024
After Eli Lilly’s Olumiant won the distinction of becoming the first med approved by the FDA to treat the follicle-attacking autoimmune disease alopecia areata, Pfizer followed up with a green ligh | The FDA signed off on Sun’s oral JAK inhibitor deuruxolitinib to treat adults with severe alopecia areata. The drug is now approved in 8 mg tablets under the brand name Leqselvi.
Pharmaceutical Technology
JULY 26, 2024
Several patients are navigating ways to access innovative gene therapies with the help of enterprising research and nonprofit organisations.
pharmaphorum
JULY 26, 2024
Leading figures from industry and academia, including AstraZeneca, have urged UK PM Keir Starmer to turn the Oxford-Cambridge region into the "crown jewel" of his industrial growth plan
Pharmaceutical Technology
JULY 26, 2024
Roche has reported a net income of SFr6.6bn ($7.4bn) in H1 2024, a 4% decline compared to SFr7.5bn ($8.5bn) in H1 2023.
Fierce Pharma
JULY 26, 2024
Johnson & Johnson’s latest attempt to get a handle on its talc litigation using the controversial Texas two-step bankruptcy strategy has once again fallen flat after a federal appeals court rul | The ruling from the Third Circuit Court of Appeals came the night before claimants in the talc litigation were set to vote on a sweeping $6.48 billion settlement proposal from J&J.
Pharmaceutical Technology
JULY 26, 2024
AbbVie has reported a 32.1% decrease in net earnings attributable to the company of $1.37bn in Q2 2024 from $2.02bn in Q2 last year.
pharmaphorum
JULY 26, 2024
Discover 5 effective strategies for biopharma companies to optimize patient recruitment in clinical trials. Learn how to enhance recruitment processes and increase patient participation.
Advertisement
This new white paper defines and details the impact of Decentralized Clinical Trials on the Pharmaceutical industry and how the impact can be measured along with steps companies can take to ensure adoption.
Pharmaceutical Commerce
JULY 26, 2024
The latest news for pharma industry insiders.
pharmaphorum
JULY 26, 2024
Discover the top 7 trends from the Cannes Lions Festival that pharma professionals should be aware of. Stay ahead of the game with these creative insights.
Drug Patent Watch
JULY 26, 2024
Chiral switching, the practice of developing a single enantiomer from a previously approved racemic drug, has been a significant strategy in the pharmaceutical industry for decades.
pharmaphorum
JULY 26, 2024
Discover the innovative work of Steven Damon, the CEO of Micron Biomedical, a company specialising in microneedle technology for improved healthcare delivery. Learn about his cutting-edge innovations in the field.
Advertisement
Planning on running clinical trials in Japan? How can you reliably supply these studies? Discover Catalent’s clinical supply packaging facility in Shiga, Japan. Strategically located between Tokyo and Osaka, and one of largest in Japan, this 6,000 square meter facility offers comprehensive services including primary and secondary clinical packaging and labelling, comparator sourcing, cold chain storage, local and global distribution, local language support and white glove service to support stud
Outsourcing Pharma
JULY 26, 2024
Discover the groundbreaking work of Cure51, co-founded by Nicolas Wolikow and Simon Istolainen, revolutionizing cancer treatment through advanced AI and biotechnology.
XTalks
JULY 26, 2024
The FDA has issued a warning about dosing errors and subsequent adverse events related to compounded semaglutide injectable products. These errors have led to some patients being hospitalized due to overdoses. These issues primarily stem from patients and healthcare providers miscalculating or incorrectly administering the drug. Compounded semaglutide products, unlike the US Food and Drug Administration (FDA)-approved ones, can vary widely in strength and packaging, making it easy for mistakes t
Outsourcing Pharma
JULY 26, 2024
The approval of donanemab marks a significant breakthrough in Alzheimer's treatment, promising transformative changes in patient care and research.
pharmaphorum
JULY 26, 2024
Pfizer's haemophilia B gene therapy is approved in EU as Durveqtix, becoming the first alternative to CSL Behring's Hemgenix
Advertisement
Clinical trial data management is increasingly challenging as studies grow in complexity. Quickly accessing and analyzing study data is vital for assessing trial progress and patient safety. In this paper, we explore real-time data access and analysis for proactive study management. We investigate using adverse event (AE) data to monitor safety and discuss a clinical analytics platform that supports collaboration and data review workflows.
Expert insights. Personalized for you.
189 
Let's personalize your content